IRLAB Therapeutics
22.12.2021 08:45:09 CET | ACCESS Newswire | Press release
GOTHENBURG, SWEDEN / ACCESSWIRE / December 22, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB (Nasdaq Stockholm: IRLAB A) IRLAB receives regulatory approval from the Swedish MPA for conducting a Phase IIb study with the investigational drug candidate pirepemat. Following approvals from regulatory authorities in additional participating countries and from ethics committees, patient recruitment will start in Q1, 2022. Recruitment is expected to continue for 18 months.
The application to conduct the Phase IIb study was filed using the Voluntary Harmonization Procedure (VHP). The VHP makes it possible to obtain a coordinated assessment of an application for a clinical trial that is to take place in several European countries. In addition to the Swedish MPA, which acts as the reference country, Polish and Spanish regulatory authorities are participating. IRLAB is also applying to regulatory authorities and ethics committees in other selected European countries.
"Pirepemat has potential to be the first treatment in a new class of drugs designed to improve balance and reduce fall injuries in people living with Parkinson's disease," said Nicholas Waters, CEO at IRLAB. "After receiving advice from regulatory authorities and in collaboration with external experts, we have designed a study to support the continued development of pirepemat, for which we have now received regulatory approval."
"Treating impaired balance and reducing risk for falls is a top priority in the battle to fight the complications of Parkinson's disease, as today these are the most troubling consequences of living with Parkinson's, leading to reduced quality of life." added Joakim Tedroff, CMO at IRLAB.
For more information
Nicholas Waters, CEO
Phone: +46 730 75 77 01
E-mail: nicholas.waters@irlab.se
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se
Åsa Hillsten, Head of IR & Corporate Communications
Phone: +46 700 81 81 17
E-mail: asa.hillsten@irlab.se
This information is information that IRLAB Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-21 23:05 CET.
About the Phase IIb study with pirepemat
The approved Phase IIb study with Pirepemat is designed as a randomized, double-blind and placebo-controlled study with the aim to evaluate the effect of pirepemat on fall frequency, as compared to a placebo, over a three-month treatment period. The planned primary outcome measure is reduction in number of falls as assessed through electronic fall diaries. The study is designed to randomize 165 patients distributed across three groups, two groups with different dose levels of pirepemat and one placebo group with 55 patients in each group. For this study, which will involve clinics across several countries in Europe, IRLAB is collaborating with a Clinical Research Organization (CRO) that has longstanding expertise and experience in running studies in Parkinson's disease.
About pirepemat (IRL752)
Pirepemat is in development for the treatment of impaired balance (postural dysfunction) and falls in Parkinson's disease (PD). Impaired balance and falls are linked to cognitive decline and the progression of Parkinson's disease. In clinical research, it has been shown that these symptoms are associated with a reduction of the neurotransmitters noradrenaline and dopamine in the frontal cortex of the brain. Pirepemat can increase the levels of these neurotransmitters in the frontal cortex and activate specific genes involved in nerve cell communication. The reduced cortical neurotransmission in PD could therefore be counteracted by treatment with Pirepemat, leading to improvement of balance and cognitive and psychiatric symptoms for people living with PD. The results from a clinical Phase IIa study indicate that Pirepemat has the potential to improve balance and reduce the risk of falls.
About IRLAB
IRLAB is a Swedish research and development company that focuses on discovery and development of novel treatments in Parkinson's disease. The company's most advanced drug candidates, Mesdopetam (IRL790), licensed to Ipsen, and Pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through its proprietary research platform, the Integrative Screening Process (ISP), IRLAB has discovered and developed all its projects within Parkinson's disease and will have an ability to also discover drug candidates for other disorders related to the central nervous system (CNS), where large and growing medical needs exist. In addition to the Phase IIb clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phases. IRLAB is listed on Nasdaq Stockholm Main Market. More information is found on www.irlab.se.
Attachments
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/679067/IRLAB-Obtains-Regulatory-Approval-to-Conduct-Phase-IIb-Study-With-Pirepemat-One-Step-Closer-To-Improving-Balance-and-Reducing-Fall-Injuries-For-People-Living-With-Parkinsons-Disease
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Pacific Avenue Capital Partners Enters into Exclusive Negotiations to Acquire ESE World, Amcor's European Waste Container Business4.5.2026 09:30:00 CEST | Press release
LOS ANGELES, CA AND PARIS, FR / ACCESS Newswire / May 4, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, announced today that an affiliate of Pacific Avenue has entered into exclusive negotiations to acquire ESE World (the "Company" or "ESE") from Amcor, one of the world's leading global packaging companies. ESE is the foremost European manufacturer of both plastic and steel waste containers and a provider of associated waste management services. The Company generates approximately €300m of revenues and serves customers across the world from its three manufacturing facilities in Germany (Neuruppin and Olpe) and France (Crissey). Under Pacific Avenue's stewardship, ESE will focus its efforts on meeting the needs of its customers and executing several growth initiatives tied to operational improvement, geographic expansion, and strategic add-on acquisitions. Pacifi
Securitas Acquires CamVision to Expand Packaged and Advanced Security Solutions in Denmark4.5.2026 09:00:00 CEST | Press release
STOCKHOLM, SE / ACCESS Newswire / May 4, 2026 / Securitas has acquired CamVision, a Danish technology driven security specialist with a strong position in retail loss prevention and electronic security solutions. The acquisition strengthens Securitas' ability to deliver reliable and scalable security solutions for micro and small singlesite businesses as well as larger, multisite clients across Denmark. For micro and small businesses, the acquisition enhances Securitas' offering of standardized, packaged security solutions that combine proven technology with dependable service delivery. For larger and multisite clients, it further strengthens Securitas' capability to deliver advanced, technology led security systems designed for complex operational environments. "With the acquisition of CamVision, we strengthen our offering for micro and small business clients, particularly within retail. By combining proven security technology with standardized service delivery, we can offer simpler,
Formerra Appoints Matt Borowiec as Chief Commercial Officer1.5.2026 15:00:00 CEST | Press release
CLEVELAND, OH / ACCESS Newswire / May 1, 2026 / Formerra, a leading distributor of performance materials, today announced the appointment of Matt Borowiec as Chief Commercial Officer (CCO). Borowiec will lead the company's commercial organization to support continued growth and global expansion while strengthening sales execution and customer success. Borowiec is a seasoned executive with over 25 years' experience in operations, commercial and P&L roles across resin manufacturing, specialty compounding, and distribution, including leadership roles at GE Plastics, PolyOne (now Avient), Transcendia, Celanese, and Kinsley Group. With this background, he is well positioned to lead Formerra's commercial strategy at this important time in the company's evolution. "Matt brings a unique combination of producer‑side and distribution experience that positions him well to strengthen alignment between our suppliers, customers, and commercial teams," said Tom Kelly, Chief Executive Officer at Forme
Global Experts call for Paradigm Shift in Medicine, Health and Education to Save Lives and Fight Escalating Health Crisis1.5.2026 14:48:00 CEST | Press release
INNSBRUCK, AUSTRIA / ACCESS Newswire / May 1, 2026 / A global consortium of 64 experts (72 entities, 5 continents) unveiled two coordinated consensus plus policy brief reports, outlining a science‑driven roadmap to confront escalating health crises and to tackle the growing burden of noncommunicable diseases (NCDs-including cardiovascular diseases, cancer, diabetes, etc.: 75% of global deaths; 82% in low-/middle income countries; 90% of all death in European region). The centerpiece is HEAL-Healthy Eating & Active Living, ideally whole‑food plant‑predominant/vegetarian-vegan diets & daily exercise outdoors/active mobility-as the minimum, first‑line standard in health and care. The authors urge immediate action on Prevention-over-Treatment and reforming education and human‑relevant science (drug failure rate from animal studies is 90-95%, and as high as 99.6% for Alzheimer disease), with a rapid shift from disease‑centered reaction to person‑centered, lifestyle‑first cure and care. Figu
Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions1.5.2026 14:00:00 CEST | Press release
Strategic acquisition is anticipated to position Datavault AI to bring CyberCatch's AI-enabled cyber risk mitigation solution into Datavault AI's SanQtum-secured edge Graphics Processing Unit ecosystem, addressing a global information security market projected to reach $240 billion in 2026 (Gartner) CyberCatch's post-quantum cryptography conversion plan is also expected to position the combined company ahead of the AI-enabled "Q-Day" quantum-attack horizon, now compressed to as early as 2029 (Google) AI-enabled adversary attacks in 2025 rose 89% year-over-year while average eCrime breakout time fell to 29 minutes, a 65% increase in adversary speed compared to 2024, per CrowdStrike's 2026 Global Threat Report, and Google Quantum AI research has now compressed the timeline for cryptographically relevant quantum computing to as early as 2029. PHILADELPHIA, PA AND SAN DIEGO, CA / ACCESS Newswire / May 1, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom